Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Authors of a ...

Older, generic medications in dermatology are cost-effective and bypass prior authorization delays, benefiting underinsured patients. Cyclosporine is effective for severe psoriasis, with careful ...

Our bodies—and guts, specifically—depend on a balance of bacteria to “maintain healthy blood sugar and cholesterol levels,” but “you gotta feed the bacteria.” So said Dr. Mehmet Oz—heart surgeon ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...

In this elderly population, overall rates of adverse events (AEs ... more than 60 countries in one or more indications including certain patients with atopic dermatitis (AD), asthma, chronic ...

Many brachycephalic dog breeds suffer with brachycephalic obstructive airway syndrome (BOAS). This can make a dog struggle to breathe, find exercise more difficult, mean they breathe noisily ...

For some, cholesterol medications may be a necessity to stay healthy. But while using these can help manage high cholesterol, ...

Hold a cool compress to the skin or plunge the affected area into a basin filled with ice water. Soak in a baking soda, colloidal oatmeal, or Epsom salt bath. Topical aloe vera gel, coconut oil ...

Medtronic’s VenaSeal Spectrum postmarket clinical trial program is highlighting the need for further patient-centric ...

Find Dermatitis Abstract stock video, 4K footage, and other HD footage from iStock. Get higher quality Dermatitis Abstract content, for less—All of our 4K video clips are the same price as HD.

Researchers have found in a new study that higher plasma omega-3 levels are linked to a reduced risk of atopic dermatitis (AD), regardless of genetic predisposition. These findings suggest that ...

Atopic dermatitis highlights from AAD 2025 include phase 3 trial results on rocatinlimab and delgocitinib, findings on tapinarof 1% cream, and early dosing data on a new JAK1/TYK2 inhibitor.